Open access
Sep 2026
Real-world healthcare resource utilization and cost burden of COVID-19 in commercially insured adults at high-risk of severe disease in the US: a retrospective database analysis.
During the Omicron era, HCRU and costs remained substantial and increased with disease severity among commercially insured patients at high risk of severe COVID-19 among commercially insured, oral antiviral therapy-eligible patients at high risk of severe disease.
Tendai Mugwagwa, Benjamin A. Abramoff, S. Karanth et al.
· Journal of Medical Economics · 0 citations